Molika Ashford
Molika Ashford covers personalized medicine and molecular diagnostics for GenomeWeb.

Articles Authored by Molika Ashford
Real-World Data Analysis Confirms Pan-Cancer Predictiveness of Foundation Medicine TMB Caller
Premium
The company worked with clinical investigators to analyze outcomes data across more than 8,000 treated individuals, reconfirming the validity of its FDA-approved TMB indication.
The company analyzed MRD status in samples from a prior failed study, showing a significant benefit from the drug for ctDNA-positive patients.
Lessons from the Phase III ZEST trial could inform ongoing and future trials as they seek to use ctDNA to prove efficacy of novel adjuvant treatments.

Data from Myriad Genetics offered early validation evidence for an expanded version of its commercial test, as well as a look into clinical impact via claims data.

The research hospital is working to further validate and refine its approach, aiming to arm clinicians with a more comprehensive tool to personalize care.

A recent survey by GenomeWeb revealed trends in the adoption and usage of various types of circulating tumor DNA assays for solid tumors.

The company believes that it has threaded the needle in terms of providing the maximum of necessary information to clinicians, while maintaining a rapid turnaround time.
Researchers Stress Specificity of Grail Multi-Cancer Detection Test in Response to Study Criticism
Premium
The authors of a commentary said they view recent study results as informative, though limited, regarding the test's performance in prostate cancer.
Investigators are trialing methods to boost sensitivity for certain cancers, and assessing measures of how tests may impact clinical care in certain screening subpopulations.

Sophia sponsored a meeting gathering early adopters, pharma partners, and others to discuss the recently launched MSK-ACCESS, and soon-to-launch MSK-IMPACT kits.